![](https://investorshub.advfn.com/uicon/726924.png?cb=1690565856)
Sunday, May 02, 2021 8:15:11 PM
Reborn1(10 weeks) - Qixleef (botanical version) & Calmz (syntehteic version); head-to-head test. A timed onset of relief from initial ingestion
REBORN1 is a 10-week open-label randomized study to evaluate the effect of inhaled QIXLEEF compared to morphine sulfate immediate release (MSIR) to improve fast onset of pain relief of breakthrough cancer pain
April 23: Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial
Plenitude© is a 4-week double-blind, randomized, placebo-controlled, parallel group design trial to evaluate the safety and efficacy of inhaled QIXLEEF™ to relieve uncontrolled cancer related pain in 78 adult patients with advanced incurable disease.
Sept 2020: Tetra Bio-Pharma Announces Plenitude Clinical Trial is Initiated
When these show proof of concept ...this will easily be a 100x stock. And the opioid crisis will have a fighting chance.
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM